OP
IMNM icon

ORG Partners’s Immunome IMNM Stock Holding History

ORG Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$18.9K Buy
+880
New +$15.4K ﹤0.01% 822

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ORG Partners's IMNM Position: Q4 2025 in Review

ORG Partners opened a new position in Immunome (IMNM) in Q4 2025: 880 shares worth $18.9K. The stake represents ﹤0.01% of the portfolio and ranks #822 among its holdings.

182 funds tracked by Wall St. Rank hold IMNM as of Q4 2025.

  • ORG Partners held 880 shares of Immunome worth $18.9K as of Q4 2025.
  • Immunome was a new ORG Partners position in Q4 2025.
  • Immunome made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #822 holding.
  • 182 funds tracked by Wall St. Rank held Immunome as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.